Comparative Pharmacology
Head-to-head clinical analysis: DRONEDARONE versus SOTYLIZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRONEDARONE versus SOTYLIZE.
DRONEDARONE vs SOTYLIZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronedarone is a multichannel blocker that inhibits potassium (IKr, IKs, IKur), sodium (INa), and calcium (ICaL) currents, and exhibits antiadrenergic effects via noncompetitive antagonism of beta-1 and beta-2 receptors. It also prolongs atrial refractoriness and slows atrioventricular conduction.
Selective beta-1 adrenergic receptor antagonist; also exhibits class III antiarrhythmic activity (potassium channel blockade), prolonging cardiac repolarization and refractory periods.
400 mg orally twice daily after meals
Initial: 80 mg orally twice daily. May increase every 2-3 days in 40-80 mg increments up to 240-320 mg/day. Maximum: 320 mg/day in divided doses.
None Documented
None Documented
Clinical Note
moderateDronedarone + Levofloxacin
"Dronedarone may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderateDronedarone + Norfloxacin
"Dronedarone may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateDronedarone + Gemifloxacin
"Dronedarone may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateDronedarone + Ibandronate
"Dronedarone may increase the QTc-prolonging activities of Ibandronate."
Terminal half-life is 13–19 hours; steady state achieved within 4–8 days.
Terminal elimination half-life is 12-16 hours in patients with normal renal function; can extend up to 30-40 hours in renal impairment, requiring dose adjustment.
Primarily fecal (≥84%) via biliary excretion; renal excretion accounts for <6% as unchanged drug.
Primarily renal excretion of unchanged drug; 85-90% eliminated unchanged in urine, with the remainder via feces (<5%) and minimal biliary excretion.
Category C
Category C
Antiarrhythmic
Antiarrhythmic